Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TNDM Stock Forecast 2026-2027
$20.03
Current Price
$1.37B
Market Cap
Buy 12
Hold 11
Sell 0
Wall St Analyst Ratings
Distance to TNDM Price Targets
+179.6%
To High Target of $56.00
+44.8%
To Median Target of $29.00
-0.1%
To Low Target of $20.00
TNDM Price Momentum
-3.0%
1 Week Change
-19.3%
1 Month Change
+22.5%
1 Year Change
-8.9%
Year-to-Date Change
-32.4%
From 52W High of $29.65
+100.7%
From 52W Low of $9.98
📊 TOP ANALYST CALLS
Did TNDM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tandem Diabetes is one of their latest high-conviction picks.
Latest TNDM Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, TNDM has a bullish consensus with a median price target of $29.00 (ranging from $20.00 to $56.00). The overall analyst rating is Buy (7.8/10). Currently trading at $20.03, the median forecast implies a 44.8% upside. This outlook is supported by 12 Buy, 11 Hold, and 0 Sell ratings.
The most optimistic forecast comes from William Plovanic at Canaccord Genuity, projecting a 179.6% upside. Conversely, the most conservative target is provided by Jonathan Block at Stifel, suggesting a 0.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TNDM Analyst Ratings
12
Buy
11
Hold
0
Sell
TNDM Price Target Range
Low
$20.00
Average
$29.00
High
$56.00
Current: $20.03
Latest TNDM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TNDM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 9, 2026 | Goldman Sachs | David Roman | Neutral | Maintains | $25.00 |
| Mar 19, 2026 | Truist Securities | Richard Newitter | Buy | Upgrade | $35.00 |
| Mar 17, 2026 | Piper Sandler | Matt O'Brien | Overweight | Upgrade | $33.00 |
| Mar 2, 2026 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $25.00 |
| Feb 23, 2026 | Truist Securities | Richard Newitter | Hold | Reiterates | $27.00 |
| Feb 23, 2026 | Lake Street | Frank Takkinen | Buy | Upgrade | $50.00 |
| Feb 20, 2026 | UBS | Danielle Antalffy | Neutral | Maintains | $22.00 |
| Feb 20, 2026 | B of A Securities | Travis Steed | Neutral | Upgrade | $30.00 |
| Feb 20, 2026 | Piper Sandler | Matt O'Brien | Neutral | Maintains | $21.00 |
| Feb 20, 2026 | Stifel | Jonathan Block | Hold | Maintains | $22.00 |
| Feb 20, 2026 | Mizuho | Anthony Petrone | Neutral | Maintains | $22.00 |
| Feb 4, 2026 | Stifel | Jonathan Block | Hold | Maintains | $20.00 |
| Jan 9, 2026 | Bernstein | Lee Hambright | Market Perform | Maintains | $25.00 |
| Dec 18, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $24.00 |
| Dec 17, 2025 | Mizuho | Anthony Petrone | Neutral | Maintains | $21.00 |
| Dec 17, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $35.00 |
| Dec 16, 2025 | Baird | Jeff Johnson | Outperform | Upgrade | $30.00 |
| Dec 11, 2025 | Citigroup | Joanne Wuensch | Neutral | Maintains | $22.00 |
| Dec 2, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $23.00 |
| Nov 10, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $17.00 |
Tandem Diabetes Care Inc. (TNDM) Competitors
The following stocks are similar to Tandem Diabetes based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TNDM
Tandem Diabetes
mkt cap
1.41B
Tandem Diabetes Care Inc. (TNDM) Financial Data
Tandem Diabetes Care Inc. has a market capitalization of $1.37B with a P/E ratio of -6.6x. The company generates $1.01B in trailing twelve-month revenue with a -20.2% profit margin.
Revenue growth is +2.7% quarter-over-quarter, while maintaining an operating margin of +2.9% and return on equity of -97.9%.
Valuation Metrics
Market Cap
$1.37B
Enterprise Value
$1.56B
P/E Ratio
-6.6x
PEG Ratio
0.0x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+2.7%
Gross Margin
+57.7%
Operating Margin
+2.9%
Net Margin
-20.2%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+21.4%
Current Ratio
2.5x
Debt/Equity
289.6x
ROE
-97.9%
ROA
-5.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tandem Diabetes Care Inc. (TNDM) Business Model
About Tandem Diabetes Care Inc.
What They Do
Develops technology solutions for diabetes management.
Business Model
The company generates revenue primarily through the sale of its advanced insulin pumps and related disposable products. Its flagship products, the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, integrate with continuous glucose monitoring systems to optimize blood glucose levels. Revenue is largely derived from the U.S. market, with additional income from developed countries through various distribution channels including direct sales and partnerships with pharmacies and healthcare providers.
Additional Information
Founded in 2006 and based in San Diego, California, the company is recognized as a global leader in automated insulin delivery technology, highlighting its commitment to improving the quality of life for insulin-dependent diabetes patients.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
2,650
CEO
Mr. John F. Sheridan
Country
United States
IPO Year
2013
Website
www.tandemdiabetes.comTandem Diabetes Care Inc. (TNDM) Latest News & Analysis
Latest News
Quick Summary
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) will release its Q1 2026 results on May 7, 2026, after market close, followed by a conference call at 4:30 pm ET. A live webcast will be available.
Why It Matters
Tandem Diabetes Care's upcoming earnings report and conference call may influence stock prices, providing insights into financial performance and future growth prospects in the diabetes tech market.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Portnoy Law Firm is investigating potential securities fraud involving Tandem Diabetes Care, Inc. (NASDAQ: TNDM) and may file a class action on behalf of investors.
Why It Matters
The investigation into potential securities fraud at Tandem Diabetes Care could lead to legal issues and financial liabilities, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength?
1 month ago
Quick Summary
Tandem Diabetes Care (TNDM) experienced significant trading volume recently, but earnings estimate revisions may hinder its short-term upward movement.
Why It Matters
Increased trading volume indicates heightened interest, but negative earnings estimate revisions suggest potential challenges ahead, impacting TNDM's stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Tandem Diabetes Care Inc. (NASDAQ: TNDM) shares rose on Tuesday after an analyst upgrade highlighted potential long-term growth opportunities.
Why It Matters
Tandem Diabetes Care's analyst upgrade suggests positive future growth potential, which can lead to increased investor confidence and potentially drive stock prices higher.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Tandem Diabetes is optimistic about growth due to new product launches and CGM integrations, but faces risks from competition and macroeconomic challenges.
Why It Matters
Tandem Diabetes' growth outlook is bolstered by new products and strong finances, but competition and economic challenges could impact performance, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) announced that its Tandem Mobi insulin delivery system is now compatible with Android smartphones in the U.S., expanding access for diabetes management.
Why It Matters
Tandem Diabetes' expansion to Android enhances market reach and accessibility for its insulin delivery system, potentially increasing sales and market share, positively impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About TNDM Stock
What is Tandem Diabetes Care Inc.'s (TNDM) stock forecast for 2026?
Based on our analysis of 31 Wall Street analysts, Tandem Diabetes Care Inc. (TNDM) has a median price target of $29.00. The highest price target is $56.00 and the lowest is $20.00.
Is TNDM stock a good investment in 2026?
According to current analyst ratings, TNDM has 12 Buy ratings, 11 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TNDM stock?
Wall Street analysts predict TNDM stock could reach $29.00 in the next 12 months. This represents a 44.8% increase from the current price of $20.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tandem Diabetes Care Inc.'s business model?
The company generates revenue primarily through the sale of its advanced insulin pumps and related disposable products. Its flagship products, the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, integrate with continuous glucose monitoring systems to optimize blood glucose levels. Revenue is largely derived from the U.S. market, with additional income from developed countries through various distribution channels including direct sales and partnerships with pharmacies and healthcare providers.
What is the highest forecasted price for TNDM Tandem Diabetes Care Inc.?
The highest price target for TNDM is $56.00 from William Plovanic at Canaccord Genuity, which represents a 179.6% increase from the current price of $20.03.
What is the lowest forecasted price for TNDM Tandem Diabetes Care Inc.?
The lowest price target for TNDM is $20.00 from Jonathan Block at Stifel, which represents a -0.1% decrease from the current price of $20.03.
What is the overall TNDM consensus from analysts for Tandem Diabetes Care Inc.?
The overall analyst consensus for TNDM is bullish. Out of 31 Wall Street analysts, 12 rate it as Buy, 11 as Hold, and 0 as Sell, with a median price target of $29.00.
How accurate are TNDM stock price projections?
Stock price projections, including those for Tandem Diabetes Care Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:57 AM UTC